Projects

Our Work

Posts tagged 340B
Cash flow analysis of the 340B rebate model

Since the 340B program’s inception, there have been debates over the importance of the program. Is the growth in the number of 340B sites, which has seen a 20-year compounded annual growth rate (CAGR) of 7.87%, a sign of the program’s vital need? Or does such growth demonstrate that the U.S. healthcare system will always grow in the direction of opacity and pricing arbitrage? The Kalderos 340B rebate model’s goal is to add transparency to the program’s pharmacy transactions in a manner that is sustainable for covered entities. The Kalderos program converts a prescription drug purchasing discount predicated on “buying low and selling high” to a retroactive rebate. 3 Axis Advisors was commissioned to study the potential cash flow impacts of the 340B rebate model proposed by Kalderos.

Read More